203 related articles for article (PubMed ID: 23884719)
1. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
Eras Z; Dizdar EA; Kanmaz G; Guzoglu N; Aksoy HT; Altunkaya GB; Canpolat FE; Dilmen U
Am J Perinatol; 2014 Jun; 31(6):463-8. PubMed ID: 23884719
[TBL] [Abstract][Full Text] [Related]
2. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
[TBL] [Abstract][Full Text] [Related]
4. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
[TBL] [Abstract][Full Text] [Related]
5. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
Fujii A; Allen R; Doros G; O'Brien S
J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
[TBL] [Abstract][Full Text] [Related]
6. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
[TBL] [Abstract][Full Text] [Related]
7. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
[TBL] [Abstract][Full Text] [Related]
8. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
Jeon GW; Oh M; Sin JB
Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
[TBL] [Abstract][Full Text] [Related]
11. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
Lamboley-Gilmert G; Lacaze-Masmonteil T;
Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
Malloy CA; Nicoski P; Muraskas JK
Acta Paediatr; 2005 Jun; 94(6):779-84. PubMed ID: 16188788
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis.
Singh N; Hawley KL; Viswanathan K
Pediatrics; 2011 Dec; 128(6):e1588-95. PubMed ID: 22123870
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of surfactant preparations in premature infants.
Trembath A; Hornik CP; Clark R; Smith PB; Daniels J; Laughon M;
J Pediatr; 2013 Oct; 163(4):955-60.e1. PubMed ID: 23769501
[TBL] [Abstract][Full Text] [Related]
15. Effects of Two Different Exogenous Surfactant Preparations on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants with Severe Respiratory Distress Syndrome.
Terek D; Gonulal D; Koroglu OA; Yalaz M; Akisu M; Kultursay N
Pediatr Neonatol; 2015 Aug; 56(4):248-55. PubMed ID: 25603725
[TBL] [Abstract][Full Text] [Related]
16. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
Ramanathan R; Bhatia JJ; Sekar K; Ernst FR
J Perinatol; 2013 Feb; 33(2):119-25. PubMed ID: 21886094
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Different Types of Natural Surfactants by Lung Ultrasound in Respiratory Distress Syndrome.
Bozkaya D; Dizdar EA; Korkut S; Ceran B; Alkan M; Oğuz ŞS
Am J Perinatol; 2021 May; 38(6):590-596. PubMed ID: 31770784
[TBL] [Abstract][Full Text] [Related]
18. Complications among premature neonates treated with beractant and poractant alfa.
Gharehbaghi MM; Sakha SH; Ghojazadeh M; Firoozi F
Indian J Pediatr; 2010 Jul; 77(7):751-4. PubMed ID: 20589459
[TBL] [Abstract][Full Text] [Related]
19. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials.
Ramanathan R
J Perinatol; 2009 May; 29 Suppl 2():S38-43. PubMed ID: 19399008
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]